Related Experiment Video

Updated: Aug 30, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

[New oncological treatment principle with imatinib]

B C Kuenen1, H M Pinedo

  • 1VU Medisch Centrum, afd. Geneeskundige Oncologie, De Boelelaan 1117, 1081 HV Amsterdam. b.kuenen@vumc.nl

Nederlands Tijdschrift Voor Geneeskunde
|November 11, 2003
PubMed

Insights

Imatinib, a targeted cancer therapy, shows success in specific cancers like CML and GIST. Its effectiveness in KIT-positive tumors depends on gain-of-function mutations, suggesting combined therapies may be beneficial.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Imatinib represents a significant advancement in cancer treatment, functioning as a tyrosine-kinase inhibitor.
  • It targets key proteins including bcr-abl, c-kit (KIT), and platelet-derived growth-factor receptor.
  • Successful applications include chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and dermatofibrosarcoma protuberans.

Purpose:

  • To evaluate the efficacy of imatinib in treating various cancers.
  • To understand the role of specific mutations, particularly in c-kit, in imatinib response.
  • To explore potential combination therapies for enhanced treatment outcomes.

Summary:

  • Imatinib's success in CML, GIST, and other cancers highlights the power of targeted molecular therapy.
  • However, its efficacy in KIT-positive tumors appears contingent on the presence of gain-of-function mutations in c-kit.
  • This observation supports further investigation into combining imatinib with traditional chemotherapy.

Impact:

  • Demonstrates the potential of rationally designed small molecules for targeted cancer therapy.
  • Identifies a specific molecular mechanism (gain-of-function mutations) influencing imatinib's effectiveness in certain cancers.
  • Provides a rationale for exploring combination strategies to overcome resistance and improve therapeutic outcomes in KIT-positive malignancies.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...